Lyell Immunopharma, Inc. - LYEL
Insiders (Form 4) · last 180 days · showing up to 200 transactions
· Form 144 is shown in the SEC filings tab
· Updating…
Visible: 0
Transaction codes:
P = Open-market purchase ·
S = Open-market sale ·
A = Grant/award ·
M = Exercise/conversion of derivative ·
G = Gift ·
F = Tax withholding ·
J = Other ·
A/D:
A = Acquired (buy/receive) ·
D = Disposed (sell/give)
| Filed | Owner | Title | Code | A/D | Shares | Price | Value | Shares after | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Jul 01, 2026 | — | J | D | 76,000.0 | 0.0 | 0.0 | 2,857,500.0 | View | |
| Jun 18, 2026 | — | J | D | 66,500.0 | 0.0 | 0.0 | 2,933,500.0 | View | |
| Jun 15, 2026 | Chief Scientific Officer | S | D | 130.0 | 18.92 | 2,459.6 | 17,808.0 | View | |
| Jun 15, 2026 | Chief Operating Officer | S | D | 89.0 | 18.92 | 1,683.88 | 17,894.0 | View | |
| Jun 15, 2026 | VP, Corporate Controller | S | D | 217.0 | 18.91 | 4,103.47 | 15,420.0 | View | |
| Jun 15, 2026 | President and CEO | S | D | 388.0 | 18.91 | 7,337.08 | 73,878.0 | View | |
| Jun 12, 2026 | — | A | A | 9,250.0 | 0.0 | 0.0 | 9,250.0 | View | |
| Jun 12, 2026 | — | A | A | 9,250.0 | 0.0 | 0.0 | 9,250.0 | View | |
| Jun 12, 2026 | — | A | A | 9,250.0 | 0.0 | 0.0 | 9,250.0 | View | |
| Jun 12, 2026 | — | A | A | 9,250.0 | 0.0 | 0.0 | 9,250.0 | View | |
| Jun 12, 2026 | — | A | A | 9,250.0 | 0.0 | 0.0 | 9,250.0 | View | |
| Jun 12, 2026 | — | A | A | 9,250.0 | 0.0 | 0.0 | 9,250.0 | View | |
| Jun 12, 2026 | — | A | A | 9,250.0 | 0.0 | 0.0 | 9,250.0 | View | |
| Jun 11, 2026 | Chief Medical Officer | S | D | 1,977.0 | 12.64 | 24,989.28 | 20,923.0 | View | |
| Mar 16, 2026 | Chief Fin. and Bus. Officer | A | A | 140,000.0 | 0.0 | 0.0 | 140,000.0 | View | |
| Mar 09, 2026 | — | P | A | 488,090.0 | 25.61 | 12,499,984.9 | 1,426,528.0 | View | |
| Mar 09, 2026 | — | P | A | 488,090.0 | 25.61 | 12,499,984.9 | 1,426,528.0 | View | |
| Feb 12, 2026 | Chief Operating Officer | S | D | 1,236.0 | 23.39 | 28,910.04 | 17,795.0 | View | |
| Feb 12, 2026 | President and CEO | S | D | 7,455.0 | 23.39 | 174,372.45 | 74,266.0 | View | |
| Feb 12, 2026 | Chief Scientific Officer | S | D | 1,671.0 | 23.39 | 39,084.69 | 16,938.0 | View | |
| Feb 11, 2026 | VP, Corporate Controller | S | D | 254.0 | 23.12 | 5,872.48 | 15,637.0 | View | |
| Feb 11, 2026 | VP, Corporate Controller | A | A | 8,750.0 | 0.0 | 0.0 | 15,891.0 | View | |
| Feb 11, 2026 | Chief Medical Officer | A | A | 50,000.0 | 0.0 | 0.0 | 50,000.0 | View | |
| Feb 11, 2026 | General Counsel | A | A | 50,000.0 | 0.0 | 0.0 | 50,000.0 | View | |
| Feb 11, 2026 | Chief Operating Officer | A | A | 65,000.0 | 0.0 | 0.0 | 65,000.0 | View | |
| Feb 11, 2026 | Chief Operating Officer | S | D | 109.0 | 23.12 | 2,520.08 | 19,031.0 | View | |
| Feb 11, 2026 | Chief Operating Officer | A | A | 4,000.0 | 0.0 | 0.0 | 19,140.0 | View | |
| Feb 11, 2026 | President and CEO | A | A | 155,000.0 | 0.0 | 0.0 | 155,000.0 | View | |
| Feb 11, 2026 | President and CEO | S | D | 438.0 | 23.12 | 10,126.56 | 81,721.0 | View | |
| Feb 11, 2026 | President and CEO | A | A | 20,000.0 | 0.0 | 0.0 | 82,159.0 | View | |
| Feb 11, 2026 | Chief Scientific Officer | A | A | 50,000.0 | 0.0 | 0.0 | 50,000.0 | View | |
| Feb 11, 2026 | Chief Scientific Officer | S | D | 147.0 | 23.12 | 3,398.64 | 18,609.0 | View | |
| Feb 11, 2026 | Chief Scientific Officer | A | A | 4,000.0 | 0.0 | 0.0 | 18,756.0 | View |